Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

Next Previous
Search
Trial Profile

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonapegsomatropin (Primary) ; Navepegritide (Primary)
  • Indications Achondroplasia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms COACH
  • Sponsors Ascendis Pharma

Most Recent Events

  • 01 May 2025 According to an Ascendis Pharma media release, the company expects topline Week 26 data from this study in Q2 2025.
  • 11 Dec 2024 Status changed from recruiting to active, no longer recruiting.
  • 03 Sep 2024 According to an Ascendis Pharma media release, the company plan to complete enrollment in the third quarter of 2024 and topline Week 26 data expected in the second quarter of 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top